United Therapeutics And Medtronic Discontinue Further Efforts To Develop & Commercialize Implantable System For Remodulin Based On Evolution Of Treatment Options, Paradigms In Pulmonary Arterial Hypertension Over Past Few Years
On June 22, 2021, United Therapeutics Corporation (the “Company”) and Medtronic, Inc. (“Medtronic”) agreed to discontinue further efforts to develop and commercialize the Implantable
